Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis

• Published in: Journal of Immunology Research Vol. 2022; pp. 1 - 10
• Main Authors: Yan, Zijun, Yang, Kun, Tang, Xiang, Bi, Yunfeng, Ding, Yuzhen, Deng, Mengyue, Xia, Die, Zhao, Yunqi, Chen, Tong
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi 20.04.2022; John Wiley & Sons, Inc; Wiley
• Subjects: Animals; Apoptosis; Biocompatibility; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Cell culture; Cell viability; Digestive system; Drug delivery; Drug delivery systems; Drug development; Drug dosages; Drugs; Experiments; Flow cytometry; Hep G2 Cells; Hepatocellular carcinoma; Hepatocytes; High performance liquid chromatography; Humans; Immunology; Injection; Kidneys; Lipids; Lipids - pharmacology; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Mice; Mice, Nude; Nanoparticles; Norcantharidin; R&D; Rats; Research & development; Spleen; Toxicity; Tumorigenesis; Vehicles; Veins & arteries; China

Malignant tumors have become the main cause of harm to human life and health. Development for new antitumor drugs and the exploration to drug carriers are becoming the concerned focus. In this study, we exploited our experiments to explore the effect of NCTD-NLC on liver cancer cells: the HepG2 cell...